View all the latest information in graft-versus-host disease, arranged by trials and clinical studies. Listed below are recently added trial updates.
KD025 for chronic GvHD: an update
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) two posters were presented by Madan Jagasia on KD025 (belumosudil).
New Drug Application submitted for belumosudil to FDA
A submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was made for the Rho-associated coiled coil kinase 2...
FDA rejects remestemcel-L for the treatment of steroid-refractory aGvHD pending further study
The FDA have issued a complete response letter rejecting the application of a Biologics License...
Remestemcel-L receives backing from the ODAC for the treatment of children with acute GvHD
On August 13, 2020, the Oncologic Drugs Advisory Committee of the U.S. Food and Drug administration deemed...
New working definition of ruxolitinib-refractory acute GvHD
Mohamad Mohty, chair of the GvHD Hub Steering Committee, and colleagues published an article in Blood to define the patient population that...
Practice-changing abstracts at ASCO and EHA 2020
Interview with GvHD Hub Co-Chair, Mohamad Mohty, providing an overview of the practice-changing abstracts from this year's virtual ASCO Annual Meeting...
Ruxolitinib shows improved overall response rate for patients with chronic GvHD
The Reach3 trial compared ruxolitinib with standard cGVHD therapies, and topline results show that the ruxolitinib...
BMT Tandem Meetings | Study design of the REACH-3 trial using ruxolitinib in steroid refractory GvHD
The REACH-3 trial will review safety and efficacy of ruxolitinib in this population of pediatric...
BMT CTN 1101
BMT CTN 1203
BMT CTN 1501